AR and breast cancer: In another study, large cohorts enabled granular analysis of BC heterogeneity, including the classification of TNBC into three metabolically distinct clusters: C1 (ceramide/fatty acid-enriched), linked to luminal androgen receptor (LAR) tumors and targetable via sphingosine-1-phosphate (S1P) inhibition; C2 (oxidative/glycosyl transfer), associated with high-risk BLIS tumors with elevated N-acetyl-aspartyl-glutamate; and C3 (low dysregulation), which has a better prognosis and is distinguishable via machine learning [152,153].